Table 3.
Average percentage of susceptibility of extended-spectrum β-lactamase producing Enterobacterales to antibiotics in Saudi Arabia between 2013–2023.
| Antibiotic |
Escherichia coli (Suspected ESBL) (n = 152) |
Escherichia coli (Confirmed ESBL) (n = 7277) |
Klebsiella pneumoniae (Confirmed ESBL) (n = 1382) |
|---|---|---|---|
| Amikacin | 87.2 | 84.6 | 83.2 |
| Amoxicillin | 0 | - | - |
| Amoxicillin/clavulanic acid | 38.7 | 39.7 | 41.6 |
| Ampicillin | 6 | 8.8 | 16.1 |
| Aztreonam | 17.3 | 5.2 | 0 |
| Cefepime | 30.2 | 28.7 | 33.3 |
| Cefoxitin | 61.5 | 78.2 | 87.7 |
| Ceftazidime | 26.3 | 14.5 | 9.6 |
| Ceftriaxone | 25.7 | 22.7 | - |
| Cefuroxime | 3.7 | - | - |
| Ciprofloxacin | 23.6 | 32.5 | 49.1 |
| Gentamicin | 51.3 | 60.1 | 46.2 |
| Imipenem | 91.7 | 90.4 | 97.9 |
| Levofloxacin | 17.4 | - | - |
| Meropenem | 98 | 88 | 99.1 |
| Nitrofurantoin | 66 | 79.1 | 38.4 |
| Piperacillin | 0 | - | - |
| Piperacillin/tazobactam | 70.9 | 68.2 | 71.3 |
| Tigecycline | 100 | 75.3 | 72 |
| Trimethoprim/sulfamethoxazole | 22.6 | 39.9 | 36.1 |
ESBL, extended-spectrum β-lactamase.